|Bid||145.38 x 800|
|Ask||146.10 x 1400|
|Day's range||144.99 - 150.75|
|52-week range||115.61 - 464.85|
|Beta (5Y monthly)||1.60|
|PE ratio (TTM)||4.98|
|Earnings date||02 Nov 2022 - 07 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||221.40|
The biotech's shares had lost nearly 15% of their value week to date as of mid-afternoon Friday, according to S&P Global Market Intelligence. On Thursday, The Wall Street Journal published an article stating that the government is planning to end its financial support for coronavirus vaccines and COVID-19 treatments. Although the coronavirus is still very much with us, cases in many jurisdictions -- such as the U.S. -- have been dropping, at times precipitously.
Is star coronavirus stock Moderna (NASDAQ: MRNA) beginning a new phase of its late-pandemic life? This might have been a concern of investors after the company announced Wednesday morning that David Meline, who has served as CFO since nearly the start of the pandemic, is stepping down from the company. After all, Meline guided Moderna to a series of impressive quarterly beats on the back of the successful coronavirus vaccine the company developed and brought to market.
Vaccines, treatments and tests will soon all be commercially available. But what that means for consumers' out-of-pocket costs is unclear.